S_M6R1 Cell Line
Invented by Prof John Lunec from Northern Institute For Cancer Research, Newcastle University
Invented at University of Newcastle upon Tyne
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 152839 |
| Parental Line | SJSA-1 |
| Host | Human |
| Tissue | Bone |
| Disease Keywords | Osteosarcoma; Multipotential sarcoma |
| Model | Cancer Model |
| Relevance | To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 cells were exposed to growth inhibitory concentrations of a MDM2 inhibitor, MI-63, and a clonal resistant cell line was generated. The p53 mediated responses of the parental and resistant cell line were compared. In contrast to the parental cell lines, p53 activation by Nutlin-3, MI-63 or ionizing radiation was not observed in the SJSA-1 derived cell line, S-M6R1. |
| Production Details | Resistant cell lines were established by exposing SJSA-1 cells to MI-63. Single cell derived colonies were isolated with cloning cylinders and the clonal population expanded in culture medium containing the MDM2/p53 antagonist refreshed weekly for 60 days. Stage 1 resistant clones were then further exposed to increased concentrations of MI-63 for 30 days to generate stage 2 resistant clones. |
| Conditional | No |
| Research Area | Apoptosis and Programmed Cell Death, Cancer, Cell Cycle, Drug Discovery & Development, Epigenetics & Nuclear Signalling |
| Cellosaurus ID | CVCL_HG09 |
References: 2 entries
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Europe PMC ID: 27323823
Drummond et al. 2016. Oncotarget. :. PMID: 27323823.
Add a reference
References: 2 entries
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Drummond et al. 2016. Oncotarget. :. PMID: 27323823.
Add a reference
